Abstract. In order to evaluate the possible role of endogenous histamine in ACTH secretion we investigated the effect of the H1 antagonist meclastine on plasma ACTH in patients with ACTH hypersecretion. Seven patients with primary adrenal insufficiency (group 1) and 5 patients with ACTH dependent Cushing's syndrome (group 2) were given an iv infusion of meclastine (4.8 mg/90 min). In patients of group 2 plasma ACTH was unaffected by meclastine infusion. However, in patients of group 1 with intact steroid feedback meclastine was followed by a significant drop in plasma ACTH as compared with ACTH levels after saline infusion (46.0 \ m=+-\4.6% vs 85.0 \ m=+-\7.0%, P < 0.01). These results suggest that histamine is involved in the control of ACTH secretion, possibly by stimulation of CRF release.
Histamine is a biogenic amine with neurotransmitter properties (Snyder & Taylor 1972) and is widely distributed in brain (Schwartz 1975 (Brownstein et al. 1974) , suggesting that histamine plays a role in CNS control of pituitary hormone secretion. In animals, histamine is suggested to be involved in the regulation of prolactin (Arakelian & Libertun 1977 ), LH (Libertun & McCann 1976) , and ADH release (Bhargava et al. 1973) , respectively. In man it has been reported that the antihistaminergic agents meclastine and dexchlorpheniramine inhi¬ bit the arginine-induced increase of hGH (Pontiroli et al. 1976 ). Administration of cimetidin, reacting antagonistic at H2 receptor sites, is followed by a rise in serum prolactin in healthy man (Carlson & Ippoliti 1977) .
Recently Rudolph et al. (1979) (Fig. 2) . During meclastine infusion a significant inhibition of ACTH release was observed as compared to saline infusion: ACTH levels were 65.3 ± 5.7 vs 89.0 ± 3.0% at 30 min (P < 0.02), 49.0 ± 4.8 vs 83.0 ± 5.0% at 60 min (P < 0.01) and 46.0 ± 4.6 vs 85.0 ± 7.0% at the end of the infusion (P < 0.01), respectively. After cessation of meclastine administration plasma ACTH levels evidently in¬ creased but still remained below starting values. There was no correlation between body weight and meclastine-induced ACTH decrease.
An effect of meclastine on plasma ACTH in patients with ACTH dependent Cushing's syn¬ drome (group 2) was not obvious. In one patient only (M.G.) a decrease of ACTH from 595 pg/ml to 390 pg/ml was observed (Fig. 3) . The decrease might be due to spontaneous fluctuations. 
Discussion
At present histamine is suggested to be a putative neurotransmitter in the brain (Schwartz 1975 (Cowan 1975 ). How¬ ever, this effect is mediated by an unspecific stress response due to pain or changes in blood pressure (Meyer & Knobil 1967 (Fehm et al. 1976 ) an intact steroid feedback control seems to be a prerequisite for the effect of acute meclastine administration on plasma ACTH concentrations.
